Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 1.00 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.90 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1628660 | 0.95 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL2654656 | 0.93 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL2654036 | 0.93 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL2653147 | 0.93 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL1796445 | 0.93 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL2655571 | 0.89 | CYP4A11 (0.79) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL18106036 | 0.89 | CYP4A11 (0.79) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| 1,4-Butanediol SCHEMBL2722579 | 0.86 | CYP4A11 (0.79) | CYP4A11CYP4F2LOXL2POLBALDH1A1 | |
| SCHEMBL70185 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| 1,3-Propanediol SCHEMBL3049205 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606625-A | Moisture-heat-resistant polyurethane heat-conducting structural adhesive and preparation method thereof | 广东德聚技术股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| EP-4692061-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | Aevis Bio, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024205319-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | 주식회사 아이비스바이오 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-5426110-A | Inhibiting dihydrofolate reductase in mammals and treating susceptible reoplasms | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995009845-A1 | PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5221760-A | Intermediates, leukotriene antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-5159097-A | An arylphosphorous compound as chemical intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
| CN-1064269-A | The 4-Pyrimdinone derivatives, their preparation method and they application in treatment | SYNTHELABO (FR) | 1992-09-09 | — | — | CN | disclosed |
| EP-0341551-B1 | ALKENOIC ACID DERIVATIVES | BAYER AG (DE) | 1992-04-01 | — | — | EP | disclosed |
| US-5041638-A | Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0162208-B1 | NOVEL N-SUBSTITUTED 3,4-DIHYDROPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0341551-A1 | Alkenoic acid derivatives | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CYP4A11 553/4885CYP4F2 2100/4885LOXL2 1318/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | CYP4A11 419/4885CYP4F2 3023/4885LOXL2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.